Register for our free email digests:
Latest From Takeda Nycomed AS
Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.
Pre Diagnostics AS is a 2.5-year-old Oslo company developing a blood-based test performed by a GP and sent to a lab for early Alzheimer’s diagnosis.
Verona Pharma plc, a drug development company focused on respiratory diseases, has appointed Ken Cunningham and Dr. Anders Ullman to its board of directors as non-executive directors – effective Sep. 10, 2015.
Pfizer pays Opko $295 million up front for global rights to develop and commercialize a long-acting recombinant human growth hormone, Roche and Novo Nordisk buy into bispecific technology and Janssen signs on with Halozyme, as Pfizer did two years earlier, to use the ENHANZE delivery platform technology with its own candidates against five targets.
- Therapeutic Areas
- Royalty Pharma AG
- North America
- Parent & Subsidiaries
- Royalty Pharma
- Senior Management
Pablo Legorreta, CEO
Susannah Gray, EVP, CFO
- Contact Info
Phone: (41)(212) 883-0200
110 East 59th St.
New York, NY 10022
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.